Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens

Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) is a top-priority pathogen causing a nosocomial infection that increases morbidity and mortality. Treatment options for CRAB are relatively limited by pharmacokinetic restrictions, such as substantial toxicity. Therefore, we must better understand this pathogen to develop new treatments and control strategies. The review aims to provide an overview of the current understanding of acquired, adaptive, and intrinsic Carbapenem-resistant pathways in <i>A. baumannii</i>, as well as its consequences on healthcare systems, particularly critical care units. The review also provides insights into how CRAB infections are currently managed worldwide and why novel therapeutic regimens are needed. The peculiarity of <i>A. baumannii</i> and its often reported virulence factors have been discussed further. In conclusion, the purpose of this review is to emphasize the current knowledge on CRAB, as it causes major worry in the field of nosocomial infections as well as overall public health.